Back to Search Start Over

The effect of socioeconomic disadvantage on prescription of guideline-recommended medications for patients with acute coronary syndrome: systematic review and meta-analysis.

Authors :
Hyun, Karice K.
Brieger, David
Woodward, Mark
Richtering, Sarah
Redfern, Julie
Source :
International Journal for Equity in Health; 8/31/2017, Vol. 16, p1-10, 10p, 3 Diagrams, 3 Charts
Publication Year :
2017

Abstract

Background: There are varying data on whether socioeconomic status (SES) affects the treatment in patients with acute coronary syndrome (ACS). Our aim was to obtain a reliable estimate of the effect of SES on discharge prescription of medications following an ACS through systematic review and meta-analysis. Methods: Medline, EMBASE and Global Health were searched systematically on 6th April 2016. Studies were eligible if the participants had ACS and reported the rate/odds of guideline-recommended ACS medications prescription (aspirin, antiplatelet, beta blocker, angiotensin co-enzyme inhibitors (ACEi)/angiotensin receptor blockers (ARB) and statin) at discharge stratified by SES. A meta-analysis was performed to pool the estimates, comparing the prescription ratio (PR) between the lowest and the highest SES groups. Results: Of 252 articles found from the search, seven met the eligibility criteria and it included 41,462 (20,986 from the lowest SES group) patients. We found that the individual/neighbourhood level SES did not affect the prescription of aspirin (PR (95% CI): 0.97 (0.91, 1.03)), but for beta blocker and statin, the lowest SES group were disadvantaged (0.84 (0.73, 0.94), 0.80 (0.62, 0.98), respectively). In contrast, ACEi were prescribed more often to the lowest individual/neighbourhood level SES group than the highest (1.13 (1.05, 1.22)). Although the risk of bias was low, there was considerable heterogeneity between the studies. Conclusions: Despite the recommendations to close the treatment gap, the rate of prescription of guideline-recommended medications in managing ACS is significantly different between patients with the lowest and the highest groups. A solution is needed to provide equitable care across the SES groups. PROSPERO Registry: Systematic review registration no.: CRD42016048503. Registered 28 September 2016. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14759276
Volume :
16
Database :
Complementary Index
Journal :
International Journal for Equity in Health
Publication Type :
Academic Journal
Accession number :
124995506
Full Text :
https://doi.org/10.1186/s12939-017-0658-z